Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: A phase II trial

Oncology Reports

Volumn 14, Issue 6, 2005, Pages 1547-1551

  Lorusso, Vito ^a   Gebbia, Vittorio ^b   Spada, Massimiliano ^a   Guida, Michele ^a   Cassano, Grazia ^a   Brunetti, Cosimo ^c   Germano, Domenico ^d   Nettis, Giuseppe ^e   Izzi, Giovanni ^a   Galetta, Domenico ^a   Giampaglia, Marianna ^a   Silvestris, Nicola ^f   Colucci, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b LA MADDALENA CANCER CENTER   (Italy)

^c Manduria Hospital   (Italy)

^d SAN CARLO HOSPITAL   (Italy)

^e Acquaviva Hospital   (Italy)

^f Operative Unit of Medical Oncology   (Italy)

Author keywords

Ifosfamide; Non small cell lung cancer; Topotecan

Indexed keywords

ANTINEOPLASTIC AGENT; IFOSFAMIDE; PLATINUM; TOPOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG RESISTANCE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METASTASIS; MIDDLE AGED; NEUTROPENIA; PATHOLOGY; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IFOSFAMIDE; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; PLATINUM; THROMBOCYTOPENIA; TOPOTECAN; TREATMENT OUTCOME;

EID: 33644690853     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.14.6.1547     Document Type: Article

References (37)

1. Ramalingam S and Belani CP: State-of-the art chemotherapy for advanced non-small cell lung cancer. Semin Oncol 31 (Suppl. 1): 68-74, 2004. (Pubitemid 38241023)
2. Kris MG: What does chemotherapy have to offer patients with advanced-stage non-small cell lung cancer? Semin Oncol 25 (Suppl. 8): 1-4,1998.
3. Fossella FV, Lynch T and Shepherd FA: Second line chemotherapy for NSCLC: establishing a gold standard. Lung Cancer 38: S5-S12, 2002. (Pubitemid 36034218)
4. Dubey S and Sciller JH: Chemotherapy for advanced non-small cell lung cancer. Hematol Oncol Clin North Am 18: 101-114, 2004. (Pubitemid 38201552)
5. Pizzolato JF and Saltz LB: The camptothecins. Lancet 361: 2235-2242, 2003. (Pubitemid 36782561)
6. Kudelka AP, Tresukosol D, Edwards CL, et al: Phase II study of intravenous topotecan as a 5 day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 14: 1552-1557, 1996. (Pubitemid 26134213)
7. Shiller JH, Kim K, Hutson P, et al: Phase II study of topotecan in patients with extensive stage small cell lung cancer: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 14: 2345-2352, 1996. (Pubitemid 26264887)
8. Robert F, Soong SJ and Wheeler RH: A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent. Am J Clin Oncol 20: 298-302, 1997. (Pubitemid 27221054)
9. MacDonald JS, Benedetti JK, Modiano M and Alberts DS: Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241). Invest New Drugs 15: 357-359, 1997. (Pubitemid 28098503)
10. Kantarjian HM, Beran M, Ellis A, et al: Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukaemia. Blood 81: 1146-1151, 1993. (Pubitemid 23067348)
11. Lynch TJ Jr, Kalish L, Strauss G, et al: Phase II study of topotecan in metastatic non-small cell lung cancer. J Clin Oncol 12: 347-352, 1994. (Pubitemid 24056409)
12. Perez-Soler R, Fossella FV, Glisson BS, et al: Phase II study of topotecan in patients with advanced non-small cell lung cancer previously untreated with chemotherapy. J Clin Oncol 14: 503-513, 1996. (Pubitemid 26051014)
13. White SC, Cheeseman S, Thatcher N, et al: Phase II study of oral topotecan in advanced non-small cell lung cancer. Clin Cancer Res 6: 868-873, 2000. (Pubitemid 30159342)
14. Brown JV III, Peters WA III, Rettenmaier MA, et al: A phase I trial of a 3-day topotecan q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum. Gynecol Oncol 79: 495-498, 2000.
15. Markman M, Kennedy A, Webster K, et al: Phase II evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer. Gynecol Oncol 79: 116-119, 2000.
16. Kerbusch T, Groenewegen G, Mathot RA, et al: Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks. Br J Cancer 90: 2268-2277, 2004. (Pubitemid 38961888)
17. Johnson DH: Ifosfamide in non-small cell lung cancer. Semin Oncol 23 (Suppl. 6): 7-10, 1996.
18. Eberhardt W and Niederle N: Ifosfamide in non-small cell lung cancer: a review. Semin Oncol 19 (Suppl. 1): 40-48,1992.
19. Rosell R, Moreno I, Maestre J, et al: Cyclophosphamide and ifosfamide combination as neoadjuvant chemotherapy for locally advanced non-small cell lung cancer: a meta-analytic review. J Surg Oncol 45: 124-130, 1990. (Pubitemid 20353699)
20. Boni C and Zanelli F: Ifosfamide in non-small cell lung cancer. Oncology 65 (Suppl. 2): 50-54, 2003. (Pubitemid 37346731)
21. Murren JR, Anderson S, Fedele J, et al: Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophoshamide in patients with refractory cancer. J Clin Oncol 15: 148-157, 1997. (Pubitemid 27021525)
22. WHO Handbook for Reporting Results of Cancer Treatment. World Health Organization, Geneva, 1979.
23. Simon R: Confidence interval for reporting results of clinical trials. Ann Intern Med 105: 429-435, 1986.
24. Gehan EA: The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chron Dis 20: 346-353,1961.
25. American Society of Clinical Oncology Treatment of Unresectable Non-Small Cell Lung Cancer Guidelines: Update 2003. J Clin Oncol 2: 330-353, 2004.
26. Fossella FV, de Vore R, Kerr RN, et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18: 2354-2362, 2000. (Pubitemid 30415821)
27. Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095-2103, 2000. (Pubitemid 30324363)
28. Gandara DR, Voakes E, Green M, et al: Activity of docetaxel in platinum-treated non-small cell lung cancer: results of a phase multicenter trial. J Clin Oncol 18: 131-135, 2000. (Pubitemid 30036346)
29. Sculier JP, Lafitte JJ, Berghmans T, et al, for the European Lung Cancer Working Party: A phase II trial testing gemcitabine as second-line chemotherapy for non-small cell lung cancer. Lung Cancer 29: 67-73, 2000. (Pubitemid 30398561)
30. Crinò L, Mosconi AM, Scagliotti G, et al: Gemcitabine as second line treatment for advanced non-small cell lung cancer: a phase II trial. J Clin Oncol 17: 2081-2085, 1999. (Pubitemid 29318838)
31. Alexopulos K, Kouroussis C, Androulakis N, et al: Docetaxel and granulocyte-colony stimulating factor in patients with advanced non-small cell lung cancer previously treated with platinum based chemotherapy: a multicenter phase II trial. Cancer Chemother Pharmacol 43: 257-262, 1999. (Pubitemid 29042495)
32. Dowlati A and Levitan N: Combination chemotherapy with topotecan for non-small cell lung cancer. Lung Cancer 41 (Suppl.4): S23-S26, 2003.
33. Weitz JJ, Marschke RF Jr, Sloan JA, et al: A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer. Lung Cancer 28: 157-162, 2000. (Pubitemid 30136415)
34. Kindler HL, Kris MG, Smith IE, et al: Phase II trial of topotecan administered as a 21 day continuous infusion in previously untreated patients with stage IIIB and IV non-small cell lung cancer. Am J Clin Oncol 21: 438-441, 1998. (Pubitemid 28480491)
35. Schneider CP, Merkel U, Grubner U, et al: Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors. J Cancer Res Clin Oncol 128: 313-318, 2002. (Pubitemid 34569352)
36. Chiara S, Tognoni A, Pastrone I, et al: Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer. Gynecol Oncol 93: 474-478, 2004. (Pubitemid 38507621)
37. Rinaldi DA, Lormand NA, Brierre JE, et al: A phase II trial of topotecan and gemcitabine in patients with previously treated, advanced non-small cell lung carcinoma. Cancer 95: 1274-1278, 2002. (Pubitemid 35013062)